嚢胞性線維症治療の世界市場の評価：薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測（2018年～2032年）

世界の嚢胞性線維症治療の市場規模は、2024年の136億1,000万米ドルから2032年に407億6,000万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで14.70%の成長が見込まれます。市場の成長は、さまざまな地域での嚢胞性線維症の負担の増大、さまざまな規制機関からの承認の増加、一般住民の嚢胞性線維症の症状に対する認知の向上によって支えられています。Cystic Fibrosis Foundationの推計によると、米国では毎年約1,000人が新たに嚢胞性線維症と診断されており、その75%超は患者が2歳になるまでに診断されています。

さらに、革新的な治療法の急速な導入と、患者基盤を拡大するための臨床試験の増加が、市場に有利な成長機会をもたらしています。嚢胞性線維症は電解質輸送系を障害するため、細胞は水分やナトリウムを保持し始め、粘液産生腺や汗に関する問題を悪化させます。そのため、嚢胞性線維症の患者は、慢性的な咳、肺虚脱、喀血、呼吸器感染症などに非常にかかりやすいです。そのため、主要な医療機関や製薬企業は、増大する脅威に対抗する治療ソリューションの開発にますます力を注いでいます。製薬企業は、標的治療、併用治療、遺伝子編集技術などを導入するための研究開発活動に多額の投資を行っています。

希少疾病用医薬品の指定や償還枠組みを含む医療政策の支援により、先進治療へのアクセスが向上しています。一方、非営利団体による啓発キャンペーンの増加と政府の取り組みの高まりは、新生児スクリーニングプログラムの拡大を通じて早期診断率を向上させ、市場の需要を押し上げています。

当レポートでは、世界の嚢胞性線維症治療市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の嚢胞性線維症治療市場の見通し（2018年～2032年）

• 市場規模分析と予測
  • 金額
• 市場シェアの分析と予測
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2024年）
• 市場マップ分析（2024年）
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 北米の嚢胞性線維症治療市場の見通し（2018年～2032年）

• 市場規模分析と予測
  • 金額
• 市場シェアの分析と予測
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • シェア：国別
• 各国の市場の評価
  • 米国の嚢胞性線維症治療市場の見通し（2018年～2032年）
  • カナダ
  • メキシコ

第6章 欧州の嚢胞性線維症治療市場の見通し（2018年～2032年）

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• トルコ
• ポーランド

第7章 アジア太平洋の嚢胞性線維症治療市場の見通し（2018年～2032年）

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第8章 南米の嚢胞性線維症治療市場の見通し（2018年～2032年）

• ブラジル
• アルゼンチン

第9章 中東・アフリカの嚢胞性線維症治療市場の見通し（2018年～2032年）

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

• 市場促進要因
• 市場の課題

第16章 市場動向と発展

第17章 規制情勢

第18章 臨床試験の概要

第19章 ケーススタディ

第20章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • Alaxia S.A.S.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd
  • Mylan NV
  • AstraZeneca plc

第21章 戦略的提言

第22章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 3. Global Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. Global Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Cystic Fibrosis Therapeutics Market Share (%), By Region, 2018-2032F
• Figure 6. North America Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 8. North America Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 9. North America Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 11. United States Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 13. United States Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 14. United States Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 17. Canada Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 18. Canada Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 21. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 25. Europe Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 26. Europe Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 30. Germany Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 31. Germany Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 34. France Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 35. France Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 38. Italy Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 39. Italy Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 42. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 46. Russia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 47. Russia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 50. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 51. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 54. Spain Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 55. Spain Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 58. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 59. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 62. Poland Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Poland Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 66. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 67. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 69. India Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 70. India Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 71. India Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 72. India Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. China Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 74. China Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 75. China Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 76. China Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Japan Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Japan Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 79. Japan Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 80. Japan Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Australia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 82. Australia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 83. Australia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 84. Australia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 85. Vietnam Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 87. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 88. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 89. South Korea Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 90. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 91. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 92. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 93. Indonesia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 94. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 95. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 96. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 97. Philippines Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 98. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 99. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 100. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 101. South America Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 102. South America Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 103. South America Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 104. South America Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 105. South America Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 106. Brazil Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 108. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 109. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Argentina Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 112. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 113. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 116. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 117. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 121. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 122. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 125. UAE Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 126. UAE Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
• Figure 129. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global cystic fibrosis therapeutics market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 13.61 billion in 2024 to USD 40.76 billion in 2032. The market's growth is supported by the increasing burden of cystic fibrosis in different regions, rising approvals from different regulatory bodies, and growing awareness about the condition among the general population. According to the estimates of the Cystic Fibrosis Foundation, about 1,000 new cases of cystic fibrosis are diagnosed each year in the United States, with over 75% of the cases being diagnosed by the time the patient is 2 years old.

Additionally, the rapid introduction of innovative therapies along with the growing number of clinical trials to expand the patient base are further providing lucrative growth opportunities for the market. Cystic fibrosis impairs the electrolyte transport system, because of which cells start retaining water and sodium, exacerbating issues related to mucus-producing glands and sweat. Thus, patients suffering from cystic fibrosis are highly susceptible to chronic coughs, lung collapses, hemoptysis, and respiratory infections, among others. Therefore, leading healthcare organizations and pharmaceutical companies are increasingly focusing on developing therapeutic solutions to combat the growing threat of the condition. The pharmaceutical companies are investing heavily in research and development activities to introduce targeted therapies, combination treatments, and gene editing technologies, among others.

Supportive healthcare policies, including orphan drug designations and reimbursement frameworks are enhancing accessibility to advanced therapies. Meanwhile, increasing awareness campaigns by nonprofit organizations coupled with the rising government initiatives are improving early diagnosis rates through expanded newborn screening programs, bolstering the market's demand.

Rising Regulatory Approvals Support Market Expansion

Increasing regulatory approvals are significantly driving the growth of the cystic fibrosis therapeutics market by facilitating the availability of innovative treatments and therapeutic solutions. In March 2025, ReCode Therapeutics, Inc. received orphan drug designation for RCT2100 from the United States Food and Drug Administration (US FDA). The investigational mRNA therapy is being developed for treating cystic fibrosis. RCT2100 is designed for delivering cystic fibrosis transmembrane conductance regulator mRNA directly to target cells in the lungs and is formulated by leveraging the company's selective organ targeting lipid nanoparticle platform.

Similarly, in February 2025, porosome reconstitution therapy for cystic fibrosis was granted orphan drug designation by the FDA. The therapy displayed increased efficacy in secretion of mucus during an analysis in which the plasma membrane of the cystic fibrosis transmembrane conductance regulator mutant cells were subjected to functional porosomes.

Additionally, the growing pipeline of clinical trials, supported by favorable regulatory environment and policies, continues to offer new opportunities for growth for the key players in the industry. Moreover, regulatory approvals often result in better reimbursement policies, boosting the accessibility of treatments more for the patient population, further bolstering the market's expansion.

Increasing Investments in Development of New Therapies Drive Market Growth

These initiatives are driving the growth of the market by fostering innovation and expanding the number of treatment options available. Investments are also accelerating research into biomarker development, personalized medicine, and gene editing technologies enabling early intervention and more effective treatments.

For instance, in January 2025, Glox Therapeutics Ltd. was awarded a grant of approximately USD 642,000 (£500,000) to advance the discovery and development of precision antibiotics that target antimicrobial-resistant lung infections in patients suffering from cystic fibrosis. Cystic fibrosis often causes thick mucus buildup in the lungs, leading to infections that become resistant to antibiotics over a period of time. Thus, addressing the urgent requirements for effective therapeutics and improving the lives of the patient population.

CFTR Modulators Account for Significant Share of the Market

The segment's growth can be attributed to the ability of these drugs to target the underlying genetic defect caused by mutations in the genes, providing a disease-modifying approach rather than addressing symptoms. This precision medicine strategy has significantly improved patient outcomes, due to improved lung functioning and increased life expectancy. Moreover, the convenience of oral administration also contributes to the popularity of CFTR modulators, allowing them to hold a significant share of the revenue.

Additionally, the rising research activities to evaluate the safety and efficacy of CFTR modulators on patients of different age groups is also supporting the segment's expansion. For instance, the La Societe Francaise de la Mucoviscidose is conducting an observational study to understand the response of CFTR modulators in patients with cystic fibrosis that are under 18. The study is estimated to conclude in July 2025.

North America Holds Major Market Share

The market's expansion in the region can be attributed to the high prevalence of cystic fibrosis in the region, increasing spendings in the healthcare sector, and strong presence of leading pharmaceutical companies. As per the estimates of the American Lung Association, approximately 40,000 people in the United States have cystic fibrosis and about one in thirty people in the country is a carrier. Moreover, research and development activities are heavily funded in North America, with major pharmaceutical corporations and research institutions collaborating to develop novel therapeutic solutions. Additionally, favorable reimbursement policies and government initiatives enhance patient access to these therapies.

Meanwhile, the Asia-Pacific is expected to witness significant growth over the forecast period due to rising investments towards the healthcare and pharmaceutical industries, improved access to innovative therapies, increasing awareness among the patient population, and growing number of research initiatives and clinical trials.

Future Market Scenario (2025 - 2032F)

The market is expected to witness significant growth in the coming years due to ongoing advancements in CFTR modulator therapies, growing awareness about the condition in developing regions, advent of various genetic editing solutions, and rising prevalence of cystic fibrosis. Additionally, increasing collaborations between biotech companies and research institutions are accelerating the development and availability of innovative solutions. Furthermore, gene therapies targeting permanent correction of cystic fibrosis transmembrane conductance regulator mutations are anticipated to enter the clinical stage over the coming years, potentially shifting the market from chronic disease management to curative approaches. Strategic partnerships, licensing deals, and public-private collaborations are also anticipated to play a crucial role in the market's expansion across the globe.

Key Players Landscape and Outlook

The key players of the market are focusing on launching new products and receiving approvals from the different regulatory bodies. For instance, in March 2025, Vertex Pharmaceuticals Incorporated's Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients that are six or older. Alyftrek combines enhances cystic fibrosis transmembrane regulator protein function, improving salt and water transport across cell membranes. This mechanism aids in reducing thick mucus buildup, a hallmark of cystic fibrosis, and improves lung functioning, slowing the progression of the disease. Such approvals are allowing the key players of the market to increase their revenues and improve their position in the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug Class
    • 4.2.1.1. CFTR Modulators
    • 4.2.1.2. Pancreatic Enzyme Supplements
    • 4.2.1.3. Mucolytics
    • 4.2.1.4. Bronchodilators
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Oral
    • 4.2.2.2. Inhaled
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Drug Class
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. CFTR Modulators
    • 5.2.1.2. Pancreatic Enzyme Supplements
    • 5.2.1.3. Mucolytics
    • 5.2.1.4. Bronchodilators
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Inhaled
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
        • 5.3.1.1.1.1. Market Share Analysis & Forecast
      • 5.3.1.1.2. By Drug Class
        • 5.3.1.1.2.1. CFTR Modulators
        • 5.3.1.1.2.2. Pancreatic Enzyme Supplements
        • 5.3.1.1.2.3. Mucolytics
        • 5.3.1.1.2.4. Bronchodilators
      • 5.3.1.1.3. By Route of Administration
        • 5.3.1.1.3.1. Oral
        • 5.3.1.1.3.2. Inhaled
      • 5.3.1.1.4. By Distribution Channel
        • 5.3.1.1.4.1. Hospital Pharmacies
        • 5.3.1.1.4.2. Retail Pharmacies
        • 5.3.1.1.4.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Turkey
• 6.9. Poland

7. Asia-Pacific Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Landscape

18. Overview of Clinical Trials

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. AbbVie Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Gilead Sciences, Inc.
  • 20.3.3. Novartis AG
  • 20.3.4. Vertex Pharmaceuticals Incorporated
  • 20.3.5. Alaxia S.A.S.
  • 20.3.6. Teva Pharmaceutical Industries Ltd.
  • 20.3.7. Merck & Co. Inc.
  • 20.3.8. F. Hoffmann-La Roche Ltd
  • 20.3.9. Mylan NV
  • 20.3.10. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer